Access in all areas? A round up of developments in market access and HTA: part 5.
| Autor: | Beattie A; Lane Clark & Peacock LLP, London, W1U 1DQ, UK., Olivença F; Lane Clark & Peacock LLP, London, W1U 1DQ, UK., Treharne C; Lane Clark & Peacock LLP, London, W1U 1DQ, UK., Ramagopalan SV; Lane Clark & Peacock LLP, London, W1U 1DQ, UK.; Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of comparative effectiveness research [J Comp Eff Res] 2024 Nov; Vol. 13 (11), pp. e240179. Date of Electronic Publication: 2024 Oct 01. |
| DOI: | 10.57264/cer-2024-0179 |
| Abstrakt: | In this latest update, we explore the recent announcement by Canada's Drug Agency (CDA-AMC, formerly CADTH) on their pilot to include the societal perspective in the evaluation of certain new medicines; a recent Office of Health Economics (OHE) report on the evaluation of HTA agency methods over time; and publications examining the impact of Project Orbis on patient access to oncology treatments. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|